Erythropoietic Protoporphyria (EPP) — Comprehensive Research Report

sup — quick orientation before the deep dive. EPP is the one where sunlight isn't a slow tan-and-burn thing but an immediate "my skin is on fire" alarm, sometimes within minutes and with almost nothing to see on the surface. The whole disease is basically one broken step at the very end of the heme assembly line: the enzyme that's supposed to tuck an iron atom into a porphyrin ring quits early, so the ring — protoporphyrin IX — piles up. That ring happens to be a tiny solar panel that turns light into cellular shrapnel. Everything else downstream flows from that one traffic jam.

1. Disease Information

What it is. Erythropoietic protoporphyria is an inherited disorder of heme biosynthesis caused by partial deficiency of ferrochelatase (FECH; EC 4.98.1.1), the terminal enzyme of the heme pathway, which inserts ferrous iron (Fe²⁺) into protoporphyrin IX (PPIX) to make heme. Reduced FECH activity → accumulation of metal-free, photoreactive PPIX in erythroid cells, plasma, skin, and liver. It is the most common cutaneous porphyria of childhood and the third most common porphyria overall. A phenotypically identical variant, X-linked protoporphyria (XLP / XLPP), arises from gain-of-function mutations in erythroid ALAS2 that overdrive substrate flux into the same pathway.

Key identifiers (MONDO verified locally via sqlite:obo:mondo): - MONDO: MONDO:0001676 (erythropoietic protoporphyria); MONDO:0008319 (protoporphyria, erythropoietic, 1) — both confirmed present in local MONDO. - OMIM: #177000 EPP1 (FECH); #618015 EPP2 (CLPX); #300752 X-linked protoporphyria (ALAS2). Gene entries: FECH *612386, ALAS2 *301300, CLPX *615611. - Orphanet: ORPHA:79278 (autosomal EPP); a distinct X-linked entry exists for XLP. ⚠verify exact XLP ORPHA code via just fetch-reference ORPHA:79278 and Orphanet lookup. - ICD-10: E80.0 (hereditary erythropoietic porphyria). ICD-11: 5C58.10. - MeSH: D046351 "Protoporphyria, Erythropoietic." - HGNC genes: FECH hgnc:3647, ALAS2 hgnc:397, CLPX hgnc:17820. (Confirm the numeric HGNC IDs with OAK before committing — repo uses lowercase hgnc: prefix.)

Synonyms / alternative names: EPP; protoporphyria; erythrohepatic protoporphyria (older term reflecting liver involvement); ferrochelatase deficiency. For the variant: X-linked dominant protoporphyria, XLPP, XLP.

Data provenance. Almost everything here is from aggregated disease-level resources — OMIM, Orphanet, GeneReviews, consensus guidelines, and cohort studies from specialist porphyria centers (Mass General, Erasmus MC Rotterdam, UCSF, Mount Sinai). The recent UK Biobank analysis is the notable population-genomic (EHR-adjacent) dataset showing systematic underdiagnosis.

2. Etiology

Disease causal factors (genetic — three molecular routes to one phenotype)

Route 1 — FECH loss-of-function (EPP1, ~90% of cases). The dominant paradigm is genetically counterintuitive and worth stating precisely: most clinically overt patients are compound heterozygous for a rare pathogenic FECH null/missense allele on one chromosome and a common hypomorphic low-expression allele, c.315-48T>C (IVS3-48C), on the other. The IVS3-48C polymorphism strengthens use of a cryptic aberrant splice acceptor, so ~40% of transcripts are aberrantly spliced and degraded by nonsense-mediated decay, lowering steady-state FECH mRNA.

"For 96% of patients, EPP results from coinheriting a rare pathogenic variant in trans of a common hypomorphic variant c.315-48T>C" (minor allele frequency ~0.05). — UK Biobank underdiagnosis study, Genetics in Medicine 2021 (PMC7796935; PMID likely 33257847 ⚠verify).

"the IVS3-48C minigene gave rise to 40% aberrantly spliced mRNA, and the IVS3-48T minigene to only 20%." — PMID:21132468, low-expression allele leads to low enzyme activity.

Residual FECH activity in symptomatic patients is roughly 10–35% of normal. A minority carry two loss-of-function FECH alleles (true autosomal recessive) — this subgroup carries a higher risk of severe liver disease and palmar keratoderma.

Route 2 — ALAS2 gain-of-function (X-linked protoporphyria, ~2–10% overall, up to ~40% in some North American cohorts). C-terminal frameshift deletions in exon 11 of ALAS2 — canonically c.1699_1700delAT (p.Met567GlufsTer2) and c.1706_1709delAGTG (p.Glu569GlyfsTer24) — truncate an autoinhibitory C-terminal region, increasing ALAS2 activity/stability. This pushes more 5-aminolevulinic acid into the pathway, so PPIX accumulates despite normal FECH.

"deletions in ALAS2 cause a … X-linked protoporphyria that, in contrast to autosomal dominant porphyrias, has close to 100% penetrance." — Whatley et al., Am J Hum Genet 2008 (PMID:18760763 ⚠verify).

Route 3 — CLPX dominant mutation (EPP2, very rare). A heterozygous CLPX p.Gly298Asp mutation in the mitochondrial AAA+ unfoldase CLPX impairs its normal turnover of ALAS, stabilizing ALAS and raising PPIX — an indirect gain-of-function on the same node.

"Cells with the mutant protein showed … increased posttranslational stability of ALAS and pathologic accumulation of PPIX." — Yien et al., PNAS 2017 (PMID:28874591).

Risk / modifying factors

Iron status: iron deficiency tends to worsen EPP (limits FECH substrate/activity and de-represses ALAS2); iron repletion may help XLP but effects are variable and sometimes worsen classic EPP — a genuinely unresolved clinical knob.
Sunlight is the phenotype trigger, not a cause. Even visible violet light (~400–410 nm) transmitted through window glass provokes symptoms.
Hepatotoxic stressors (alcohol, fasting, drugs that induce ALAS/CYP, intercurrent illness) can precipitate hepatic decompensation once liver disease exists.
Genetic ancestry: IVS3-48C allele frequency is markedly higher in East/Southeast Asian and Japanese populations than in Northern Europeans, shaping regional penetrance patterns.
Consanguinity matters for the rare biallelic-LOF autosomal recessive form.

Protective factors

Homozygosity for the high-expression IVS3-48T allele in trans to a pathogenic FECH mutation → subclinical/latent carriers (higher residual FECH). This is the single strongest protective genetic factor.
Constitutive skin melanin (darker pigmentation) is modestly photoprotective — the mechanistic basis for the afamelanotide/dersimelagon therapeutic strategy.

Gene–environment interaction

The defining GxE story is genotype (FECH residual activity) × light dose × iron availability. The trans-allele expression level sets a PPIX ceiling; ambient light converts that latent chemistry into phenotype; iron status tunes flux at both FECH and ALAS2.

3. Phenotypes

Suggested HPO anchors in brackets.

Acute cutaneous phototoxicity (near-universal, ~99%; onset infancy–early childhood). - Painful, burning/stinging/prickling photosensitivity within minutes of sun exposure, often with little visible sign at first — a hallmark that causes years of diagnostic delay. [HP:0000992 Cutaneous photosensitivity], pain [HP:0012531]. - Erythema [HP:0000988 skin rash / HP:0010783 erythema], edema, pruritus. Blistering is uncommon (distinguishes EPP from other cutaneous porphyrias like PCT). - Severity moderate–severe and highly disabling; course episodic/acute-on-chronic (each light exposure is a discrete event), lifelong.

Chronic skin changes (frequent with cumulative exposure). - Waxy thickening/lichenification over the knuckles and dorsal hands, shallow linear/pitted scars on the nose and cheeks, leathery hyperkeratosis. [HP:0000962 Hyperkeratosis], scarring [HP:0100699].

Hepatobiliary. - Cholelithiasis — PPIX-rich pigment gallstones, often at a young age [HP:0001081 Cholelithiasis]. Common. - Protoporphyric hepatopathy — mild transaminase elevation in up to ~20% of LOF-FECH patients; severe cholestatic liver disease / acute liver failure in ~2–5%. [HP:0001394 Cirrhosis], cholestasis [HP:0001396], hepatic failure [HP:0001399].

"Liver involvement is observed in 5%–20% of patients harbouring loss-of-function FECH variants and its manifestations are heterogeneous, ranging from mildly elevated liver transaminases, cholelithiasis to severe acute cholestatic hepatitis/liver failure." — Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management (PMC11669082).

Hematologic. - Mild microcytic, hypochromic anemia with low ferritin/iron stores in a substantial fraction [HP:0001935 Microcytic anemia]. Usually mild and non-hemolytic.

Secondary / systemic. - Vitamin D deficiency and reduced bone mineral density from lifelong sun avoidance [HP:0100512 Decreased vitamin D level], osteopenia [HP:0000938]. - Motor polyneuropathy — a rare, dramatic complication seen in acute protoporphyric liver failure.

Quality of life. Impact is large and under-appreciated: patients organize life around darkness, curtail schooling/work/socializing, and report anxiety and depression. QoL instruments respond strongly to treatment — in an Austrian afamelanotide cohort the EPP-QoL score rose from a median of 11.11 to 79.17 and phototoxic burn-tolerance time from 15 to 250 minutes (JDDG 2023, Seidl-Philipp et al.).

4. Genetic / Molecular Information

Causal genes. | Gene | Locus | Mechanism | Disorder | OMIM | |---|---|---|---|---| | FECH | 18q21.31 | Loss of function | EPP1 (~90%) | #177000 | | ALAS2 | Xp11.21 | Gain of function | XLP | #300752 | | CLPX | 15q22.31 | Dominant, stabilizes ALAS | EPP2 (rare) | #618015 |

Pathogenic variants. - FECH: >180 reported alleles — missense, nonsense, splice-site, small indels, and large multi-exon/whole-gene deletions. Most are private/family-specific null alleles. The recurring functional partner is the common IVS3-48C hypomorph (gnomAD MAF ~0.05 in Europeans; considerably higher in East Asians). ClinVar RCV000000592 covers the c.315-48T>C allele. - ALAS2: recurrent C-terminal exon-11 frameshifts (c.1699_1700delAT, c.1706_1709delAGTG); additional deletions reported (e.g., a four-base ALAS2 deletion in a Chinese pedigree, PMC7186625). - CLPX: single dominant p.Gly298Asp to date.

Variant classification / origin. Germline. FECH nulls → loss of function; ALAS2 C-terminal deletions → gain of function; CLPX → dominant with a gain-of-function-like effect on ALAS stability. No somatic involvement (this is not a neoplastic process).

Modifier genes. The FECH IVS3-48C allele is the canonical modifier/permissive locus. Iron-regulatory genes and ALAS2 iron-responsive-element biology modulate flux. Zygosity for LOF FECH modifies liver-disease risk.

Epigenetics / chromosomal abnormalities. No established disease-driving epigenetic marks; the IVS3-48C effect is a splicing phenomenon, not methylation. Large FECH deletions are the relevant structural lesions (detectable by MLPA/CMA when sequencing is negative). No aneuploidy association.

5. Environmental Information

Environmental factor (defining): visible light, ~400–410 nm (violet/Soret band) — the phenotype's obligatory trigger. Passes through window glass; even fluorescent/operating-room lighting can burn.
Lifestyle: alcohol and fasting stress the liver; smoking and hepatotoxins accelerate hepatopathy in susceptible patients. Sun-avoidance lifestyle itself causes secondary vitamin D deficiency.
Occupational: outdoor work is often untenable; even phototherapy lamps and surgical lights are hazards (surgical-light phototoxic burns are a documented intra-operative risk in EPP patients).
Infectious agents: none causal. (Hepatitis A/B are relevant only as avoidable liver insults — hence vaccination is recommended.)

6. Mechanism / Pathophysiology

Core causal chain (upstream → downstream):

Enzymatic block at the terminal heme step. FECH deficiency (or ALAS2/CLPX overdrive) → the metal-insertion step fails or is outrun. [GO:0004325 ferrochelatase activity; GO:0006783 heme biosynthetic process]. FECH is an inner-mitochondrial-membrane enzyme [GO:0005743].
PPIX accumulation in erythroid cells. The bone-marrow reticulocyte/erythroblast is the dominant source of excess metal-free protoporphyrin IX [CHEBI:15430 protoporphyrin IX]; in XLP, zinc-protoporphyrin rises too. Cell types: [CL:0000765 erythroblast; CL:0000558 reticulocyte].
Systemic distribution. Lipophilic PPIX loads into erythrocytes and plasma, deposits in skin, and is excreted into bile — the only elimination route (not renal).
Cutaneous phototoxicity (the acute arm). PPIX absorbs violet light → excited triplet state → type I/II photochemistry generating singlet oxygen and other reactive oxygen species [GO:0006979 response to oxidative stress] → oxidative injury to dermal microvascular endothelium [CL:0000115], mast-cell degranulation [CL:0000097], and complement activation → immediate neurogenic/inflammatory pain and edema. [GO:0009416 response to light stimulus].
Protoporphyric hepatopathy (the chronic/severe arm). PPIX is cholestatic and directly hepatotoxic: it precipitates as crystalline deposits in hepatocytes [CL:0000182] and bile canaliculi, injuring cholangiocytes [CL:0002326] and Kupffer cells → cholestasis → reduced biliary PPIX clearance → further hepatic PPIX retention. This feed-forward vicious cycle is what converts stable disease into fulminant liver failure.

"Protoporphyric hepatopathy results from the accumulation of protoporphyrin in hepatocytes and bile canaliculi, with toxic effects on cholangiocytes and Kupffer cells leading to cholestasis." — liver-management consensus guidelines (PMC10818013).

Protein dysfunction. FECH is a homodimeric [2Fe-2S]-cluster mitochondrial enzyme; pathogenic variants reduce catalytic activity or destabilize the protein. ALAS2 C-terminal deletions remove an autoinhibitory element (structural gain of function). CLPX G298D disrupts unfoldase-mediated ALAS turnover.

Metabolic changes. The lesion is confined to the heme biosynthetic pathway (KEGG map00860); the phenotype is a substrate-accumulation disease — no broad energy-metabolism derangement, though secondary anemia reflects constrained heme output.

Immune involvement. Innate/inflammatory rather than autoimmune — ROS-driven mast cell and complement activation in skin; sterile inflammatory hepatic injury.

Molecular profiling. The bitopertin mechanistic work used CD34⁺-derived and iPSC-derived erythroid cultures to show that limiting glycine (via GlyT1) reduces PPIX — an in vitro substrate-limitation demonstration (PMC12435829 / PMC12435834). Erythroid-specific transcriptional control of ALAS2 (GATA1, iron-responsive element) is the relevant expression biology.

7. Anatomical Structures Affected

Skin [UBERON:0002097 skin of body], specifically sun-exposed sites — face, dorsal hands, ears, nose (bilateral, symmetric, light-distribution).
Liver [UBERON:0002107] and biliary tract / gallbladder [UBERON:0002110 gallbladder; UBERON:0002394 bile duct].
Bone marrow [UBERON:0002371] — the erythroid production source of excess PPIX.
Blood / erythrocytes [UBERON:0000178 blood].
Subcellular: mitochondrion [GO:0005739] (site of FECH, ALAS2, and terminal heme synthesis); mitochondrial inner membrane [GO:0005743].
Secondary: bone [UBERON:0002481] (low BMD from vitamin D deficiency); peripheral nerves (post-liver-failure neuropathy).

8. Temporal Development

Onset: typically infancy to early childhood — often the first prolonged sun exposures. Screaming/crying with sun in a nonverbal infant is a classic (and easily missed) presentation.
Onset pattern of episodes: acute (minutes) with each light exposure; underlying disease is chronic and lifelong.
Progression: skin phenotype is generally stable in severity across life (not progressive neurodegeneration-style). The dangerous variable is hepatic: usually absent/mild, but can convert to rapid, life-threatening acute liver failure, sometimes precipitated by an intercurrent stressor.
Course: non-remitting baseline; phototoxic events are episodic/provoked. Symptom-free periods require darkness, not spontaneous remission.
Critical windows: liver-function surveillance is the key intervention window — catching rising PPIX/LFTs before decompensation is what changes outcomes.

9. Inheritance and Population

Inheritance patterns. - EPP1: operationally behaves as autosomal recessive / pseudodominant — clinical disease usually requires a rare LOF FECH allele in trans to the common IVS3-48C hypomorph (a "one severe hit + one weak hit" model). Rare biallelic-LOF families are frankly recessive. HPO inheritance: [HP:0000007 Autosomal recessive] for the two-hit model; some pedigrees historically labeled autosomal dominant with low penetrance. - XLP: X-linked [HP:0001417]; near-100% penetrance in hemizygous males, variable in heterozygous females depending on X-inactivation (skewed lyonization can make carrier females symptomatic — PMID:25615817). - EPP2 (CLPX): autosomal dominant [HP:0000006].

Penetrance / expressivity. Penetrance of the FECH mutation is gated by the trans-allele expression level — the reason many obligate carriers are asymptomatic. Expressivity is variable (mild latent to severe with hepatopathy).

Epidemiology. - Prevalence: commonly cited 1:75,000 (Netherlands) to 1:200,000 (Wales); worldwide range ~1:17,000–1:100,000. Europe-wide diagnosed prevalence ≈ 0.00092%. - Underdiagnosis: UK Biobank genetics suggest true prevalence is ~2.3× higher than clinically estimated (corrected ≈ 0.0059%); diagnosis is frequently delayed >10 years.

"the prevalence of erythropoietic protoporphyria is 2.3 times higher than previously estimated in Europe" — UK Biobank underdiagnosis analysis (Genetics in Medicine 2021).

Sex ratio: roughly equal for EPP1; male predominance among symptomatic XLP.
Ancestry: higher IVS3-48C frequency in East/Southeast Asian populations; XLP proportion notably higher in North American cohorts (~40% in one Mount Sinai series, PMC3646094).
Age distribution: overwhelmingly diagnosed in children once symptomatic; carriers span all ages.

10. Diagnostics

The decisive biochemical test: markedly elevated total erythrocyte protoporphyrin with a predominance of metal-free (non-zinc) PPIX. [LOINC candidates for erythrocyte protoporphyrin; confirm exact LOINC codes].

Fractionation is critical and distinguishes entities:
EPP1: mostly metal-free PPIX (zinc-PP fraction typically <15%).
XLP: substantially higher zinc-protoporphyrin fraction (~15–50%).
Iron deficiency / lead poisoning: predominantly zinc-protoporphyrin (helps exclude mimics).
Plasma fluorescence scan: emission peak at ~634 nm — a rapid confirmatory screen.
Biochemistry pattern: urinary porphyrins are typically normal (PPIX is not water-soluble) — a useful negative that separates EPP from acute hepatic porphyrias.

Genetic testing. - FECH: sequencing for the rare pathogenic allele plus targeted IVS3-48C genotyping (essential — the common allele won't be flagged as pathogenic on its own). MLPA/deletion analysis when sequencing finds only one or no variant (large FECH deletions). - ALAS2: targeted exon 11 analysis for C-terminal frameshifts when biochemistry suggests XLP. - CLPX: consider in FECH/ALAS2-negative dominant pedigrees. - Gene panels (porphyria panels) and WES are reasonable when the phenotype is atypical.

Monitoring labs. LFTs (surveillance for hepatopathy), ferritin/iron studies, 25-OH vitamin D, CBC.

Imaging / pathology. Not required for diagnosis. Liver biopsy in hepatopathy shows birefringent, Maltese-cross PPIX deposits under polarized light; abdominal imaging for gallstones.

Differential diagnosis. Other cutaneous porphyrias (PCT, variegate, hereditary coproporphyria — but those blister and have abnormal urinary porphyrins), solar urticaria, polymorphous light eruption, phototoxic drug reactions, hydroa vacciniforme. The immediate painful, largely non-blistering photosensitivity with normal urinary porphyrins is the discriminating fingerprint.

Screening. No newborn screening. Cascade genetic testing of first-degree relatives (for both the LOF allele and IVS3-48C) is appropriate for counseling.

11. Outcome / Prognosis

Life expectancy: normal for the great majority; the disease's weight is on quality of life, not survival — except for the small subset with progressive liver disease.
Principal mortality driver: protoporphyric liver failure (~2–5%). Rare but potentially fatal, and can be abrupt.
Morbidity: chronic pain, profound activity restriction, social/occupational limitation, secondary vitamin D deficiency/low BMD, and cholelithiasis. QoL scores are low at baseline and highly treatment-responsive.
Prognostic factors: biallelic LOF FECH genotype, very high/rising erythrocyte PPIX, and abnormal LFTs flag higher hepatic risk. Erythrocyte PPIX level tracks disease burden and is the practical biomarker.
Recovery: phototoxic symptoms are fully reversible with light avoidance/therapy; liver failure is not reversible without transplant ± marrow replacement.

12. Treatment

The therapeutic logic splits cleanly: (a) shield the solar panel or darken the skin over it, (b) turn down PPIX production at the source, and (c) rescue the liver when the feed-forward cycle runs away.

Photoprotection & supportive care (foundation). - Strict sunlight avoidance, protective clothing, and opaque physical sunscreens with visible-light reflectants (zinc oxide, titanium dioxide, iron-oxide-tinted formulations — chemical UV filters alone are useless here because the culprit is visible light). [MAXO:0000950 supportive care]. - Vitamin D supplementation; hepatitis A/B vaccination to protect the vulnerable liver.

Melanocortin-1-receptor agonists (approved / advanced pipeline). - Afamelanotide (Scenesse) — α-MSH analog MC1R agonist, subcutaneous controlled-release implant every ~60 days; stimulates eumelanin to raise the phototoxic threshold. EMA-approved 2014, FDA-approved 2019. Randomized and long-term real-world data show longer pain-free sun exposure and large QoL gains. [MAXO/NCIT:C15986 Pharmacotherapy; therapeutic_agent: afamelanotide].

"Afamelanotide … increased duration of sun exposure without pain and improved quality of life." — Langendonk et al., N Engl J Med 2015 (PMID:26132941).

Dersimelagon (MT-7117) — oral, non-peptide selective MC1R agonist; phase 2 (ENDEAVOR) met its primary endpoint (increased pain-free sun-exposure time), with phase 3 in EPP/XLP (NCT extension NCT05005975). A genuinely convenient oral alternative to implants if approved. [therapeutic_modality: SMALL_MOLECULE].

Substrate-limiting / disease-modifying (investigational). - Bitopertin — oral glycine transporter-1 (GlyT1) inhibitor that starves the very first heme step of glycine, lowering PPIX at the source (potentially disease-modifying rather than just photoprotective). The randomized AURORA phase 2 (75 patients, 20/60 mg vs placebo, 17 weeks) showed dose-dependent whole-blood PPIX reductions of −21.6% (20 mg) and −40.7% (60 mg); sunlight-tolerance improvements did not reach significance against a strong placebo response.

"Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial." — PMID:41390126 ⚠verify (recent; fetch before quoting).

Older adjuncts (limited evidence): oral β-carotene (historical, modest at best), cysteine, N-acetylcysteine, antioxidants, narrowband UVB skin-hardening.

Liver disease management (escalating). - Suppress erythroid PPIX output and promote elimination: cholestyramine / activated charcoal (interrupt enterohepatic PPIX recycling), ursodeoxycholic acid, IV hemin/heme arginate (represses erythroid ALAS), RBC exchange transfusion / plasmapheresis, iron optimization. - Liver transplantation for acute protoporphyric liver failure — life-saving but NOT curative, because the marrow keeps overproducing PPIX and can damage the graft. [MAXO:0010039 organ transplantation]. - Allogeneic hematopoietic stem cell transplantation (HSCT) — the only curative therapy, as it replaces the erythroid PPIX source; performed after liver transplant in the combined strategy for severe cases.

"The strategy of hematopoietic stem cell transplantation after liver transplantation cures erythropoietic protoporphyria and prevents recurrent erythropoietic protoporphyria from damaging the allograft." — liver-disease consensus guidelines (PMC10818013).

Pharmacogenomics. No routine PGx gating, but genotype is the therapeutic map: XLP (ALAS2) is the strongest rationale for source-reduction approaches (bitopertin, hemin), while FECH-EPP with hepatopathy anchors the transplant/HSCT pathway.

13. Prevention

Primary prevention: none (inherited) — but genetic counseling and cascade family testing identify at-risk relatives, and prenatal testing / preimplantation genetic diagnosis are available for known familial variants. [MAXO:0000079 genetic counseling].
Secondary prevention: photoprotection to prevent phototoxic injury; annual LFT/PPIX surveillance to catch hepatopathy early; vitamin D repletion; hepatitis A/B vaccination; avoidance of alcohol and hepatotoxins.
Tertiary prevention: aggressive early management of rising PPIX/abnormal LFTs to head off liver failure; timely referral to a specialist porphyria center with transplant capability.
Public-health angle: raising clinician awareness is itself a prevention lever — the >10-year diagnostic delay is the biggest modifiable failure point.

14. Other Species / Natural Disease

Taxonomy of natural/model disease: mouse [NCBITaxon:10090], cattle [NCBITaxon:9913], zebrafish [NCBITaxon:7955].
Bovine protoporphyria — a naturally occurring FECH-deficiency disease documented in cattle (notably Limousin), with photosensitivity paralleling human EPP; catalogued in OMIA. [VBO breed term for Limousin — verify].
Orthologous genes: Fech, Alas2, Clpx are conserved across mammals and in zebrafish; the pathway is deeply conserved (heme synthesis is ancient), making cross-species mechanism transfer strong.
Comparative biology: natural bovine and induced rodent/fish models reproduce both the photosensitivity and, in FECH-null rodents, the hepatopathy — a nice illustration of evolutionary conservation of the PPIX-phototoxicity mechanism.
Zoonosis: not applicable (non-infectious, non-transmissible).

15. Model Organisms

Fech^m1Pas mouse (BALB/c background; a chemically induced Fech point mutation, Tutois et al.) — the workhorse model; homozygotes recapitulate cutaneous photosensitivity + cholestatic liver disease + biliary PPIX deposits, capturing both arms of human disease. [evidence_source: MODEL_ORGANISM]. ⚠verify PMID (Tutois 1991, J Clin Invest).
Ferrochelatase c.315-48C modifier mouse — engineered to model the human low-expression splice modifier (PMC5374324), directly testing the IVS3-48C mechanism in vivo.
CLPX mouse models — probe the ALAS-stabilization mechanism of EPP2.
Zebrafish dracula (fech mutant) — classic vertebrate heme-synthesis model showing porphyrin accumulation and light-dependent hemolysis/phenotype.
Chemically induced protoporphyria — griseofulvin or DDC (3,5-diethoxycarbonyl-1,4-dihydrocollidine) feeding induces PPIX accumulation and protoporphyric hepatopathy in rodents; a standard tool for studying the liver arm.
Cellular / in vitro models — CD34⁺-derived and iPSC-derived erythroid cultures used to demonstrate GlyT1/glycine-limitation reduction of PPIX (the bitopertin mechanism; PMC12435829/PMC12435834). [evidence_source: IN_VITRO].
Model resources: MGI (Fech, Alas2, Clpx), ZFIN (fech), OMIA (bovine protoporphyria), IMPC/IMSR for allele availability.
Recapitulation vs limitations: rodent Fech models capture skin + liver disease well; the compound-heterozygous IVS3-48C human genetics (a splicing hypomorph) is not naturally reproduced by simple null alleles — the engineered c.315-48C mouse exists specifically to close that human-model gap. Consider a HUMAN_MODEL_MISMATCH discussion note if you're modeling the splice-modifier arm.

Priority citation set for the KB entry

Verified via PubMed/PMC search this session (safe to fetch and quote): - PMID:26132941 — Langendonk et al., afamelanotide RCT, NEJM 2015. - PMID:28874591 — Yien et al., CLPX/EPP2, PNAS 2017. - PMID:21132468 — FECH IVS3-48C low-expression allele → low enzyme activity. - PMID:30704898 — Balwani, EPP & XLP pathophysiology/genetics/management review. - PMID:25615817 — X-inactivation and XLP phenotype in females. - Blood 2023;141:2921–2931 — Karp Leaf & Dickey, "How I treat EPP and XLP" (fetch for PMID). - PMC10818013 — consensus guidelines, protoporphyria-related liver dysfunction. - PMC7796935 — UK Biobank underdiagnosis (Genet Med 2021).

⚠verify before quoting (cited from memory or secondary mention): PMID:18760763 (Whatley ALAS2 2008), the AURORA bitopertin primary paper (PMID:41390126), the dersimelagon phase 2 primary paper, and the Fech^m1Pas mouse origin paper. Run just fetch-reference PMID:XXXX and confirm the snippet is an exact abstract substring before any of these lands in an evidence block — standard DR-hallucination hygiene per the repo SOP.

Sources

Bottom line for curation: EPP is a clean, well-understood substrate-accumulation disease that maps neatly onto the dismech pathograph — one enzymatic block (FECH↓, or ALAS2↑ / CLPX for the variants), PPIX buildup, then a forking downstream into an acute photochemical skin arm (light → singlet oxygen → dermal injury) and a chronic hepatic arm (PPIX cholestasis → feed-forward liver failure). The genetics deserve special care in the entry: model the two-hit FECH-null + IVS3-48C hypomorph genotype explicitly (it's the whole reason penetrance is weird), and give X-linked protoporphyria its own subtype block with the ALAS2 gain-of-function mechanism rather than folding it in silently.